Clinical Trial Update: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

This entry reports a Phase 3 trial of UGN-103 for low-grade, intermediate-risk non-muscle invasive bladder cancer and indicates the study is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• UGN-103 (UGN-103)

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING